Market Place
Sourcing Support
Autobahn Therapeutics to Present at Multiple Investor Conferences
12 Nov 2024 //
BUSINESSWIRE
Autobahn Therapeutics Receives FDA Clearance For ABX-002
22 Oct 2024 //
BUSINESSWIRE
Autobahn Initiates AMPLIFY Phase 2 Trial Of ABX-002
16 Sep 2024 //
BUSINESSWIRE
Autobahn Therapeutics Joins Multiple Upcoming Investor Conferences
10 Sep 2024 //
BUSINESSWIRE
Autobahn Therapeutics Raises 100M In Series C For CNS Drug Pipeline
24 Jul 2024 //
BUSINESSWIRE
Charles River Labs And Autobahn Labs Boost Academic Drug Discovery
24 Jul 2024 //
BUSINESSWIRE
Autobahn Therapeutics to Participate in the Leerink Partners Biopharma
20 Jun 2024 //
BUSINESSWIRE
Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days
13 Mar 2024 //
BUSINESSWIRE
Autobahn Announces Positive Topline Results from Phase 1 Study of ABX-002
07 Nov 2023 //
BUSINESSWIRE
Autobahn Therapeutics to Present at Upcoming Investor Conferences
04 Oct 2023 //
BUSINESSWIRE
Autobahn Completes Dosing in Phase 1 Multiple-ascending Dose Study of ABX-002
11 Sep 2023 //
BUSINESSWIRE
Autobahn to Present at Morgan Stanley 21st Annual Global Healthcare Conference
06 Sep 2023 //
BUSINESSWIRE
Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment forMDD
18 Apr 2023 //
BUSINESSWIRE
Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days
23 Mar 2023 //
BUSINESSWIRE
Autobahn begins dosing in Phase I major depressive disorder treatment trial
30 Nov 2022 //
CLINICALTRIALSARENA
Autobahn raises funds for ABX-002 advancement to treat depression
09 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002
02 Aug 2021 //
BUSINESS WIRE
Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas,
11 May 2021 //
BUSINESSWIRE
Autobahn Presents Preclinical, Proof of Concept Data for ABX-002
19 Apr 2021 //
BUSINESSWIRE
Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002
16 Apr 2021 //
BUSINESSWIRE
Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA
01 Dec 2020 //
BUSINESSWIRE
Autobahn Therapeutics Appoints Business Leader, Scott Forrest, Ph.D., as Chief Business Officer
15 Jul 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.